Results for progenitor cell translation from English to Maltese

assessment of progenitor cell yields
analiżi tal-produzzjoni taċ-ċelluli proġenitriċi

in peripheral blood progenitor cell mobilisation in normal donors
f’donaturi b’saħħithom taħt proċedura ta’ mobilizzazzjoni ta’ pbpc

special precautions in patients undergoing peripheral blood progenitor cell mobilisation
prekawzjonijiet speċjali f’pazjenti taħt proċedura ta’ mobilizzazzjoni ta’ pbpc

special precautions in normal donors undergoing peripheral blood progenitor cell mobilisation
prekawzjonijiet speċjali f’donaturi b’saħħithom taħt proċedura ta’ mobilizzazzjoni ta’ pbpc

busilvex is administered prior to the haematopoietic progenitor cell transplantation (hpct).
busilvex għandu jittieħed qabel it-trapjant taċ-ċelluli ematopojetiċi proġenitriċi (hpct).

there is no known antidote to busilvex other than haematopoietic progenitor cell transplantation.
m’hemm l-ebda antidot għall-busilvex barra mit-trapjant taċ-ċelluli ematopojetiċi proġenitriċi.

mobilisation of peripheral blood progenitor cells (pbpc)
mobilizzazzjoni ta’ ċelluli proġenituri tad-demm periferali (pbpc)

for the mobilisation of pbpc in normal donors prior to allogeneic peripheral blood progenitor cell transplantation
għall-mobilizzazzjoni ta’ pbpc f' donaturi b’saħħithom qabel trapjant alloġenejiku ta’ ċelluli proġenitriċi tad-demm periferali

mobilisation of peripheral blood progenitor cells (pbpcs).
il-mobilizzazzjoni ta’ ċelluli proġenituri tad-demm periferali (pbpcs).

tepadina administration must be supervised by a physician experienced in conditioning treatment prior to haematopoietic progenitor cell transplantation.
l-għoti ta’ tepadina għandu jiġi sorveljat minn tabib li għandu esperjenza fil-kura ta’ kondizzjonament qabel it-trapjant taċ-ċelluli ematopojetiċi proġenitriċi.

for the mobilisation of pbpc in patients undergoing myelosuppressive or myeloablative therapy followed by autologous peripheral blood progenitor cell transplantation
għall-mobilizzazzjoni ta’ pbpc f’pazjenti taħt kura majelosoppressiva jew majeloablativa segwit bit-trapjant awtolgu ta’ ċelluli proġenitriċi tad-demm periferali

in the absence of haematopoietic progenitor cell transplantation, the recommended dosage of busilvex would constitute an overdose of busulfan.
9 jikkonstitwixxi doża eċċessiva ta ’ busulfan.

the committee decided that busilvex’ s benefits are greater than its risks as conditioning treatment prior to haematopoietic progenitor cell transplantation.
il- kumitat iddeċieda li l- benefiċċji ta 'busilvex huma ogħla mir- riskji tiegħu għat- trattament ta' kundizzjonament qabel it- trapjant ta 'ċelluli ematopojetiċi proġenitriċi.

biograstim is indicated for the mobilisation of peripheral blood progenitor cells (pbpc).
biograstim huwa indikat għall-mobilizzazzjoni taċ-ċelluli proġenitriċi tad-demm periferali(pbpc).

filgrastim ratiopharm is indicated for the mobilisation of peripheral blood progenitor cells (pbpc).
filgrastim ratiopharm huwa indikat għall-mobilizzazzjoni taċ-ċelluli proġenitriċi tad-demm periferali(pbpc).

use of filgrastim, either alone or after chemotherapy, mobilises haematopoietic progenitor cells into peripheral blood.
l-użu ta’ filgrastim, waħdu jew wara kimoterapija, jimmobilizza ċ-celluli proġenitriċi ematopojetiċi għal ġod-demm periferiku.

use of filgrastim, either alone, or after chemotherapy, mobilises haematopoietic progenitor cells into peripheral blood.
l-użu ta’ filgrastim, jew waħdu, jew wara l-kimoterapija, jimmobilizza ċ-ċelluli ematopojetiċi proġenituri fid-demm periferali.

use of filgrastim, either alone, or after chemotherapy, mobilises haematopoietic progenitor cells into the peripheral blood.
l-użu ta’ filgrastim, jew waħdu, jew wara l-kimoterapija, jimmobilizza ċ-ċelluli ematopojetiċi proġenituri fid-demm periferali.

in these patients, erythropoietin deficiency and a reduced response of erythroid progenitor cells to endogenous erythropoietin both contribute significantly towards their anaemia.
f’dawn il-pazjenti, kemm in-nuqqas fl-eritropojetina kif ukoll ir-rispons imnaqqas taċ-ċelluli eritrojdi proġenituri jikkontribwixxu b’mod sinifikattiv għall-anemija.

an m2 bone marrow ( 5% and ≤ 25% blasts) and appearance of normal progenitor cells
mudullun tal-għadma m2 ( 5% u ≤ 25% ċelluli primittivi) u d-dehra ta' ċelluli normali proġenitriċi